Measuring quality is important in determining whether patients are getting the appropriate care they need, and according to Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, quality measures should cater to the patient’s unique needs.
Measuring quality is important in determining whether patients are getting the appropriate care they need. Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, explained that measures should be specific to the patient’s unique needs.
She explained that a part of her and her team’s work is to define what quality measures they believe are important for doctors to look at, which means considering the patient’s specific disease type and trying to understand whether the individual received the types of treatment and medications he or she needed. Dr Bosserman said that from this view of a patient’s needs requires a new definition for the standard of quality care.
Where City of Hope offers a set standard for what quality of care looks like and allows physicians and health plans to use it as a benchmark, Dr Bosserman explained that CancerLinQ, the platform being developed by the American Society of Clinical Oncology, looks at the big picture: overall health outcomes and overall costs.
Both programs are equally exciting according to Jason C. Goldwater, MA, MPA, senior director, National Quality Forum. “I think anytime that you’re watching an organization gather data from its 37 different oncology practices, and really using fairly sophisticated analytic tools on what will be an extensive data set, I think it piques everyone’s interest in the quality measurement community,” Mr Goldwater said.
Mr Goldwater said that “big data” has become a very popular term, largely because of the innovative, emerging means of storing electronic data, like for example the cloud and various data warehousing programs. He added, “I think we’re just beginning to scratch the surface of what we’re going to be able do with that and I think there’s great interest in how CancerLinQ is going to be used to create measures or refine measures that are already existing.”
However, Dr Bosserman underscored the importance of optimizing patient-physician meetings by providing data systems that are easier to use for the physician. She concluded that discrete data are critical for the decisions health plans make as well as in measuring quality and patient outcomes.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More